We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-5.11%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$549M
AUM Growth
+$38.2M
Cap. Flow
+$95.8M
Cap. Flow %
17.45%
Top 10 Hldgs %
48.43%
Holding
55
New
15
Increased
11
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$42.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$18.6M
3
ALKS icon
Alkermes
ALKS
+$13.6M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.1M
5
REPL icon
Replimune Group
REPL
+$12.5M

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$20.9M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$12.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$9.7M
4
MLYS icon
Mineralys Therapeutics
MLYS
+$9.31M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$6.65M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$10M 1.83%
+198,500
New +$9.24M
INSM icon
27
Insmed
INSM
$21.4B
$9.97M 1.82%
+394,872
New +$9.03M
OKUR
28
OnKure Therapeutics
OKUR
$154M
$8.89M 1.62%
116,706
+8,374
+8% +$570K
APGE icon
29
Apogee Therapeutics
APGE
$10.1B
$8.52M 1.55%
+400,000
New +$8.81M
GOSS icon
30
Gossamer Bio
GOSS
$82.9M
$5.19M 0.95%
+6,230,272
New +$7.18M
IGMS
31
DELISTED
IGM Biosciences
IGMS
$5.14M 0.94%
615,317
+115,317
+23% +$978K
HRTX icon
32
Heron Therapeutics
HRTX
$93.9M
$4.88M 0.89%
4,737,368
– –
ACRS icon
33
CALL
Aclaris Therapeutics
ACRS
$726M
$4.79M 0.87%
+700,000
New +$5.98M
CERE
34
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$4.69M 0.85%
+215,000
New +$5.38M
ABOS icon
35
Acumen Pharmaceuticals
ABOS
$155M
$4.46M 0.81%
1,074,101
+22,834
+2% +$141K
GBIO
36
DELISTED
Generation Bio
GBIO
$3.88M 0.71%
102,254
– –
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.76M 0.68%
+86,302
New +$3.08M
TERN
38
DELISTED
Terns Pharmaceuticals
TERN
$3.25M 0.59%
+645,899
New +$4.1M
TRML
39
DELISTED
Tourmaline Bio
TRML
$2.81M 0.51%
100,000
+33,397
+50% +$978K
GRCL
40
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$1.67M 0.3%
579,667
-1,688,390
-74% -$6.17M
SLDB icon
41
Solid Biosciences
SLDB
$794M
$1.14M 0.21%
450,403
-134,055
-23% -$520K
AMAM
42
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
$1.12M 0.2%
+97,700
New +$1.33M
ACRS icon
43
PUT
Aclaris Therapeutics
ACRS
$726M
– –
-255,000
Closed -$2.64M
AMLX icon
44
Amylyx Pharmaceuticals
AMLX
$2.26B
– –
-968,795
Closed -$20.9M
APLS
45
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-94,700
Closed -$8.63M
DTIL icon
46
Precision BioSciences
DTIL
$180M
– –
-248,991
Closed -$3.93M
FDMT icon
47
4D Molecular Therapeutics
FDMT
$532M
– –
-350,000
Closed -$6.32M
MCRB icon
48
Seres Therapeutics
MCRB
$46.8M
– –
-46,903
Closed -$4.49M
MLYS icon
49
Mineralys Therapeutics
MLYS
$2.25B
– –
-546,059
Closed -$9.31M
MRSN
50
CALL
DELISTED
Mersana Therapeutics
MRSN
– –
-2,800
Closed -$230K
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Great Point Partners held 55 positions worth $549M, up 7.5% from $511M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Great Point Partners deployed $95.8M of net new capital in Q3 2023, opening 15 new positions and adding to 11 existing holdings. Its largest new stake was UroGen Pharma: 2,620,545 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Gracell Biotechnologies Inc. American Depositary Shares, an estimated $6.17M trimmed.

  • Great Point Partners's largest Q3 2023 buy was UroGen Pharma: 2,620,545 shares worth $36.7M.
  • Great Point Partners added most to Alkermes in Q3 2023, an estimated $13.6M increase.
  • Great Point Partners's biggest Q3 2023 reduction was Gracell Biotechnologies Inc. American Depositary Shares, cutting an estimated $6.17M.
  • Great Point Partners fully exited Amylyx Pharmaceuticals in Q3 2023, selling an estimated $20.9M.
  • Great Point Partners's ten largest holdings make up 48% of its $549M portfolio in Q3 2023.
  • Great Point Partners opened 15 new positions and closed 13 in Q3 2023.
  • Great Point Partners's portfolio value rose 7.5% quarter-over-quarter to $549M.

Based on Great Point Partners's 13F filing for Q3 2023, filed 14 Nov 2023.